Back Back
ASH 2022: Multiple Myeloma

CME

Key Studies in Multiple Myeloma: Independent Conference Coverage of ASH 2022

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits™

Released: March 21, 2023

Expiration: March 20, 2024

CME/CE Information

Activity

Progress
1
Course Completed

Introduction

At the 64th American Society of Hematology (ASH) Annual Meeting held on December 10-13, 2022, in New Orleans, Louisiana, new clinical trial data were reported for multiple myeloma (MM). In this module, Shaji K. Kumar, MD, and Sagar Lonial, MD, review and discuss the clinical implications of key studies presented at the meeting.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with MM do you provide care for in a typical month?

Which of the following findings were reported in the phase II ASCENT trial evaluating intensive therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (dara-KRd) for 6 cycles of induction followed by 6 cycles of dara-KRd consolidation and maintenance therapy with lenalidomide and daratumumab for an additional twelve 4-week cycles for patients with high-risk smoldering MM (SMM)?

A 74-year-old patient with newly diagnosed MM is considering treatment options. They may be eligible for reduced intensity melphalan (MEL) conditioning and autologous stem cell transplantation (ASCT) but are unsure if they want to undergo the procedure. Considering relevant recent data from the phase III DSMM XIII trial, what would you tell this patient regarding treatment with lenalidomide/dexamethasone (Rd) and reduced-intensity high-dose therapy (HDT)-ASCT followed by lenalidomide maintenance compared with Rd until disease progression?

Which of the following key findings was reported in the phase II MonumenTAL-1 trial evaluating talquetamab, a G protein–coupled receptor, class C, group 5, member D (GPRC5D)-targeted bispecific antibody, in patients with relapsed/refractory (R/R) MM after ≥3 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-38 (CD38) antibody or after disease progression on established therapies?

BACK | NEXT